Status:
COMPLETED
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Acute Myelocytic Leukemia
Acute Lymphocytic Leukemia
Eligibility:
All Genders
10-55 years
Phase:
PHASE1
PHASE2
Brief Summary
This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.
Eligibility Criteria
Inclusion
- Patients with a diagnosis that qualifies them for a DUCBT
- Absence of recent active mold infection
- Adequate organ function
- Availability of eligible donor material
Exclusion
- Pregnancy or breastfeeding women and women of child-bearing potential unless two acceptable forms of contraception are being used
- Human immunodeficiency virus (HIV) infection
- Active infection
- Extensive prior chemotherapy
- Prior myeloablative allotransplantation or autologous transplant.
Key Trial Info
Start Date :
January 9 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 3 2016
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01474681
Start Date
January 9 2012
End Date
October 3 2016
Last Update
December 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55455